Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025 PMV Pharmaceuticals is collaborating with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center to support an... Read More

Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025 Dose-limiting toxicities observed in rezatapopt and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) combination arm of... Read More

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 60% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis from Phase 2 monotherapy expected by mid-2025 Eligibility criteria in ongoing Phase 1b rezatapopt and pembrolizumab combination arm of PYNNACLE trial adjusted to... Read More

PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June.... Read More

BOSTON & PRINCETON, N.J. / May 29, 2024 / Business Wire / Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid... Read More

First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 2024,... Read More

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT) First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS WT advanced solid tumors PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a... Read More

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting Of the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response with a seven-month median duration of response and... Read More

Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type, remains on track to initiate in Q1 2024 Phase 1 analysis from the PYNNACLE Phase 1/2 study of rezatapopt in a subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C... Read More

PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc . (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David Mack, Ph.D., President and Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference taking place in... Read More

Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30% Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend cash runway to end of 2026 PC14586 registrational Phase 2 clinical trial remains on track to initiate... Read More

PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs) Michael Carulli promoted to Chief Financial Officer Robert Ticktin, General Counsel, will expand responsibilities to include management of Operations Tim Smith, Senior Vice President, Head of Corporate Development, will expand... Read More

Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven months An overall response rate of 38% observed at the recommended Phase 2 dose of 2000 mg daily for the intended Phase 2 population of TP53 Y220C and KRAS wild-type... Read More

Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in multiple tumor types including ovarian, breast, prostate, lung, and endometrial cancer with median duration of response of seven months Confirmed overall response rate of 38% at Recommended Phase 2 Dose of 2000 mg daily (6/16... Read More

PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on... Read More

Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutation Company to host KOL webinar on October 12, 2023 to review data and provide regulatory update PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology... Read More

Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; updated Phase 1 data expected in 2H 2023 Concluded successful End-of-Phase 1 FDA meeting with alignment on recommended Phase 2 dose and key elements of single arm, Phase 2 registrational portion of PYNNACLE study Ongoing enrollment in... Read More

PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference taking place in... Read More

Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected in 2H 2023 Commenced enrollment in the combination arm of the PYNNACLE study with PC14586 and KEYTRUDA ® (pembrolizumab) PRINCETON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq:... Read More

Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023 Enrolled first patient in combination arm of the PYNNACLE study with PC14586 and KEYTRUDA ® (pembrolizumab) Cash, cash equivalents, and marketable securities of $243.5 million as... Read More

PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March. Cowen’s 43rd Annual Health Care Conference... Read More